key: cord-0968884-e8zdn019 authors: Heath, Paul T; Le Doare, Kirsty; Khalil, Asma title: Inclusion of pregnant women in COVID-19 vaccine development date: 2020-08-11 journal: Lancet Infect Dis DOI: 10.1016/s1473-3099(20)30638-1 sha: c10755e0110b357b0de7bec60ef3a4ccd6bd5891 doc_id: 968884 cord_uid: e8zdn019 nan On Dec 31, 2019, the Wuhan Municipal Health Commission (Wuhan, China), reported a cluster of cases of pneumonia to WHO. A novel coronavirus was identified-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-and the outbreak was declared as a Public Health Emergency of International Concern in January, 2020. The virus subsequently spread rapidly throughout China and other countries worldwide, and on March 11, 2020, the outbreak was declared a pandemic. Since March 11, 2020, the virus has continued to spread, causing substantial morbidity and mortality in many countries. In previous outbreaks of other coronavirus infections, such as severe acute respiratory syndrome and Middle East respiratory syndrome, serious complications were reported in pregnant women. 1,2 During the 2009 influenza A H1N1 pandemic, pregnant women accounted for 5% of US deaths, while representing only 1% of the US population. 3 However, despite more than 18 million reported cases of COVID-19 worldwide, 4 understanding of the effect of SARS-CoV-2 on pregnant women, fetuses, and infants is incomplete. A systematic review and meta-analysis of mainly small case series reported that a high proportion of women with confirmed COVID-19 infection had preterm birth (<37 weeks [22%]) and caesarean delivery (48%). 5 Estimated rates of admission to the intensive care unit among pregnant women (7%) were higher than those of non-pregnant women (4%) and around 1ยท9% of infants born to these women tested positive for SARS-CoV-2. 5 Thus far, the literature has focused on symptomatic women with confirmed infection, however, this might underestimate the rates of admission, since many individuals are asymptomatic. 6 Many important questions remain unanswered, including the extent of asymptomatic or mild infection and the effect of COVID-19 on miscarriage, intrauterine fetal growth restriction, congenital ano malies, longterm growth, and neurodevelopmental outcomes. The effects of Zika virus infection in pregnancy are a sobering reminder of the possible burden of viral infection in pregnant women. 7 A comprehensive document published by the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies Working Group in 2019 provided ethical guidance for preparedness, research, and response for pregnant women and vaccines against emerging epidemic threats. 8 The document identified a number of specific strategies to promote the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens. The WHO Scientific Advisory Group of Experts welcomed this initiative and suggested it should be extended to include lactating women. 9 The need for a vaccine against COVID-19 is indisputable. A particular consideration is that for many of the vaccine candidates and platforms being actively considered, such as nucleic acids, viral vectors, and novel adjuvants, no trials have been done in pregnant women. 10 At present, the evidence base for pregnant women and COVID-19 is limited. Although pregnant women are not considered to be at increased risk of complications compared with non-pregnant women, they seem to be (at least) of similar risk. An additional consideration for pregnant women with COVID-19, especially among those with severe infection, is that access to effective drugs might be restricted, considering the scarcity of data on most drugs in pregnancy. The need for intensive care support among patients with COVID-19 is of particular concern for pregnant women who reside in low-income and middle-income countries. 5 These factors suggest that pregnant women should be considered as candidates for preventative measures, of which vaccination is the gold standard. Since the immune responses to vaccination in pregnant women cannot be assumed from that of nonpregnant women and because the assessment of safety of vaccination in pregnancy is unique, pregnant women should be included in appropriately designed vaccine trials. A number of specific strategies can be suggested to ensure that pregnant women and lactating women are included in vaccine research. These strategies include ensuring that at least some of the candidates prioritised for development should use platforms and adjuvants that would be suitable for use in pregnancy; the need to include developmental toxicology studies early in the clinical development programme; and the need to plan systematic collection of data on immunogenicity and pregnancy-specific indicators of safety from participants (and their infants) who are not aware of their pregnancy at the time of exposure in vaccine trials. These strategies should only be employed with the agreement of pregnant women and this dialogue must start now. A clear need exists to plan for the inclusion of pregnant and lactating women in the development and deployment of COVID-19 vaccines and early investment in this field. The inclusion of these women will ensure that pregnant women and their infants can benefit from vaccine candidates that prove successful and help ensure that they will ultimately be protected against COVID-19. To enable the inclusion of pregnant and lactating women in the development of COVID-19 vaccines, three key questions need to be answered: what is the shortterm and long-term burden of COVID-19 in pregnant women, the fetus, and infants (in all populations and ethnic groups); do pregnant women wish to be vaccinated against COVID-19 and participate in such trials; and which of the candidate COVID-19 vaccines are suitable for pregnant women and should be the focus of early clinical trials? Such an approach will also establish the precedent for the enabling frameworks and guidance that mainstream the inclusion of pregnant women in future vaccine development. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes Universal screening for SARS-CoV-2 in women admitted for delivery An update on Zika virus infection Pregnant women and vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response -conclusions and recommendations SARS-CoV-2 vaccines: status report We declare no competing interests.